nach oben

Drugs in R&D

Erschienen in:

01.03.2008 | Adis R&D Profile

Mifamurtide

CGP 19835, CGP 19835A, L-MTP-PE, Liposomal MTP-PE, MLV 19835A, MTP-PE, Muramyltripeptide Phosphatidylethanolamine

Erschienen in: Drugs in R&D | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Excerpt

Mifamurtide is a conjugate of muramyl tripeptide linked to dipalmitoyl phosphatidyl ethanolamine; the phospholipid facilitates incorporation of the peptide into liposomes. The agent stimulates macrophages to seek out and destroy cancer cells. The compound was originated by Novartis (formerly CIBA-Geigy), and is being developed by IDM Pharma for osteosarcoma. Mifamurtide is being reviewed by regulatory authorities in the US and EU for this indication. …

Immuno-Designed Molecules. IDM Acquires Assets from the American Company Jenner. Media Release: 9 Apr 2003. Available from URL: http://www.idm-biotech.com

IDM Pharma Inc. IDM and GENESIS Pharma Sign an Exclusive Marketing Agreement for Junovan(TM) in South East Europe. Media Release: 21 Feb 2006. Available from URL: http://www.idm-pharma.com

IDM Pharma Inc. IDM and Medison Pharma Sign an Exclusive Marketing Agreement for Junovan(TM) in Israel. Media Release: 14 Mar 2006. Available from URL: http://www.idm-pharma.com

IDM (Immuno-Designed Molecules). IDM and Cambridge Laboratories Sign an Exclusive Marketing Agreement for Junovan(TM) (Mepact) in the United Kingdom and Ireland. Media Release: 21 Jun 2005. Available from URL: http://www.idm-biotech.com

IDM Pharma Inc. IDM Pharma to Raise $25 Million in Registered Direct Offering. Media Release: 21 Jun 2007. Available from URL: http://www.idm-pharma.com

IDM Pharma Inc. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma. Media Release: 27 Aug 2007. Available from URL: http://www.idm-pharma.com

IDM Pharma. IDM Pharma Submits New Drug Application to the FDA for Junovan™ (mifamurtide) in the Treatment of Osteosarcoma. Media Release: 27 Oct 2006. Available from URL: http://www.idm-pharma.com

IDM Pharma. IDM Pharma Submits Filing for European Market Approval of Mepact™ (mifamurtide, Junovan™ in the US) in the Treatment of Osteosarcoma. Media Release: 8 Nov 2006. Available from URL: http://www.businesswire.com

IDM Pharma Inc. IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program. Media Release: 2 Nov 2007. Available from URL: http://www.idm-pharma.com

10.

IDM. Mepact, IDM’ss Most Advanced Product, Receives ‘Orphan Medicinal Product’ Designation for the Treatment of Osteosarcoma in the European Union. Media Release: 8 Jul 2004. Available from URL: http://www.idm-biotech.com

11.

Verweij J, Judson I, Steward W, et al. Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/ PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group Study. European Journal of Cancer: Part A 30A: 842–843, No. 6, 1994PubMedCrossRef

12.

Kahn J, Chernoff D, Sinangil F. Phase 1 dose escalation MTP-PE study of an HIV-1 GP120 vaccine in sero-negative adults. AIDS Research and Human Retroviruses 9 (Suppl. 1): 112, Oct 1993

13.

IDM. IDM Pharma Announces Acceptance for Review of the NDA for Junovan™ (Mifamurtide). Media Release: 27 Dec 2006. Available from URL: http://www.idm-pharma.com

14.

Dinney CPN, Utsugi T, Fidler IJ, et al. Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or gamma-interferon. Cancer Research 52: 1155–1161, 1 Mar 1992PubMed

15.

Asao T, Shibata HR, Batist G, et al. Eradication of hepatic metastases of carcinoma H-59 by combination chemoimmu-notherapy with liposomal muramyl tripeptide, 5-fluorouracil, and leucovorin. Cancer Research 52: 6254–6257, 15 Nov 1992PubMed

16.

Bezault J, Walsh C, Tarcsay L, et al. Analysis of the antimetastatic effects of synthetic muramyl tripeptide (CGP 19835A) encapsulated in liposomes in combination with other immuno-modulatory agents and chemotherapeutic drugs. In Vivo 7: 487–491, Nov–Dec 1993

17.

Kleinerman ES, Snyder JS, Jaffe N. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. Journal of Clinical Oncology 9: 259–267, Feb 1991PubMed

18.

Lazdins JK, Woods-Cook K, Walker M. The lipophilic muramyl peptide MTP-PE is a potent inhibitor of HIV replication in macrophages. AIDS Research and Human Retroviruses 6: 1157–1161, Oct 1990PubMedCrossRef

19.

Fujimaki W, Itoh K, An T. Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP-19835A lipid). Cancer Biotherapy 8: 307–318, No. 4, 1993PubMedCrossRef

20.

Gianan MAV, Kleinerman ES. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update. Cancer Biotherapy and Radiopharmaceuticals 13: 363–368, No. 5, 1998PubMedCrossRef

Titel: Mifamurtide
CGP 19835, CGP 19835A, L-MTP-PE, Liposomal MTP-PE, MLV 19835A, MTP-PE, Muramyltripeptide Phosphatidylethanolamine
Publikationsdatum: 01.03.2008
Verlag: Springer International Publishing
Erschienen in: Drugs in R&D / Ausgabe 2/2008
Print ISSN: 1174-5886
Elektronische ISSN: 1179-6901
DOI: https://doi.org/10.2165/00126839-200809020-00007

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Mifamurtide

CGP 19835, CGP 19835A, L-MTP-PE, Liposomal MTP-PE, MLV 19835A, MTP-PE, Muramyltripeptide Phosphatidylethanolamine

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Mepolizumab

Faropenem Medoxomil

Difficulties in the Production of Identical Drug Products from a Pharmaceutical Technology Viewpoint

ATP Production and TCA Activity are Stimulated by Propionyl-L-Carnitine in the Diabetic Rat Heart

Microdosing Studies in Humans

Preclinical Efficacy and Safety Pharmacology of SUN-1334H, a Potent Orally Active Antihistamine Agent